These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Niwa H; Satoh T; Matsushima Y; Hosoya K; Saeki K; Niki T; Hirashima M; Yokozeki H Clin Immunol; 2009 Aug; 132(2):184-94. PubMed ID: 19464955 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of galectin-9 in islets prolongs grafts survival via downregulation of Th1 responses. Chou FC; Kuo CC; Wang YL; Lin MH; Linju Yen B; Chang DM; Sytwu HK Cell Transplant; 2013; 22(11):2135-45. PubMed ID: 23067523 [TBL] [Abstract][Full Text] [Related]
7. Tim-3 ligand galectin-9 reduces IL-17 level and accelerates Klebsiella pneumoniae infection. Wang F; Xu J; Liao Y; Wang Y; Liu C; Zhu X; Chen ZK; Sun Z Cell Immunol; 2011; 269(1):22-8. PubMed ID: 21453908 [TBL] [Abstract][Full Text] [Related]
8. Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Wang F; Wan L; Zhang C; Zheng X; Li J; Chen ZK Immunobiology; 2009; 214(5):342-9. PubMed ID: 19362679 [TBL] [Abstract][Full Text] [Related]
9. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. Nagahara K; Arikawa T; Oomizu S; Kontani K; Nobumoto A; Tateno H; Watanabe K; Niki T; Katoh S; Miyake M; Nagahata S; Hirabayashi J; Kuchroo VK; Yamauchi A; Hirashima M J Immunol; 2008 Dec; 181(11):7660-9. PubMed ID: 19017954 [TBL] [Abstract][Full Text] [Related]
14. Elevated Galectin-9 Suppresses Th1 Effector Function and Induces Apoptosis of Activated CD4 Yang S; Wang J; Chen F; Liu G; Weng Z; Chen J Inflammation; 2017 Jun; 40(3):1062-1071. PubMed ID: 28393295 [TBL] [Abstract][Full Text] [Related]
15. Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Kanzaki M; Wada J; Sugiyama K; Nakatsuka A; Teshigawara S; Murakami K; Inoue K; Terami T; Katayama A; Eguchi J; Akiba H; Yagita H; Makino H Endocrinology; 2012 Feb; 153(2):612-20. PubMed ID: 22186414 [TBL] [Abstract][Full Text] [Related]
16. The amelioration of composite tissue allograft rejection by TIM-3-modified dendritic cell: Regulation of the balance of regulatory and effector T cells. Wang Y; Zheng Z; Zhu X; Han J; Dong M; Tao K; Wang H; Wang Y; Hu D Immunol Lett; 2016 Jan; 169():15-22. PubMed ID: 26561949 [TBL] [Abstract][Full Text] [Related]
17. Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease. Oikawa T; Kamimura Y; Akiba H; Yagita H; Okumura K; Takahashi H; Zeniya M; Tajiri H; Azuma M J Immunol; 2006 Oct; 177(7):4281-7. PubMed ID: 16982862 [TBL] [Abstract][Full Text] [Related]
18. The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma. Chen Z; Dong D; Zhu Y; Pang N; Ding J FASEB J; 2021 Mar; 35(3):e21401. PubMed ID: 33559190 [TBL] [Abstract][Full Text] [Related]
19. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells. Matesic D; Valujskikh A; Pearlman E; Higgins AW; Gilliam AC; Heeger PS J Immunol; 1998 Nov; 161(10):5236-44. PubMed ID: 9820495 [TBL] [Abstract][Full Text] [Related]
20. Tim-2 up-regulation and galectin-9-Tim-3 pathway activation in Th2-biased response in Schistosoma japonicum infection in mice. Qi Y; Song XR; Shen JL; Xu YH; Shen Q; Luo QL; Zhong ZR; Wang W; Chu DY; Song WJ Immunol Lett; 2012 May; 144(1-2):60-6. PubMed ID: 22469568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]